


Listing of Claims


1. (Withdrawn) A method comprising administering



- or a pharmaceutically acceptable salt or a prodrug thereof,
to a mammal suffering from, or at risk of developing, a prostaglandin D₂ or a
prostaglandin DP receptor mediated condition or disease.
2. (Withdrawn) The method of claim 1 wherein said condition or disease is related to immune function.
3. (Withdrawn) The method of claim 1 wherein said condition or disease is related to HIV infection.
4. (Withdrawn) The method of claim 1 wherein said condition or disease is an inflammatory disorder.
5. (Withdrawn) The method of claim 1 wherein said condition or disease is selected from the group consisting of asthma, dermatitis, and edema.
6. (Withdrawn) The method of claim 1 wherein said condition or disease is an allergic condition.
7. (Withdrawn) The method of claim 1 wherein said condition is a dermatological allergy.
8. (Withdrawn) The method of claim 1 wherein said condition is an ocular allergy.
9. (Withdrawn) The method of claim 1 wherein said condition is a respiratory allergy.
10. (Withdrawn) The method of claim 1 wherein said condition or disease is selected from the group consisting of nasal congestion, rhinitis, and asthma.

11. (Withdrawn) The method of claim 1 wherein said condition or disease is related to pain.
12. (Withdrawn) The method of claim 1 wherein said condition or disease is selected from the group consisting of arthritis, migraine, and headache.
13. (Withdrawn) The method of claim 1 wherein said condition or disease is associated with the gastrointestinal tract.
14. (Withdrawn) The method of claim 1 wherein said condition or disease is selected from the group consisting of peptic ulcer, heartburn, reflux esophagitis, erosive esophagitis, non-ulcer dyspepsia, infection by *Helicobacter pylori*, alryinitis, and irritable bowel syndrome.
15. (Withdrawn) The method of claim 1 wherein said condition or disease is selected from the group consisting of hyperalgesia and allodynia.
16. (Withdrawn) The method of claim 1 wherein said condition or disease is related to mucus secretion.
17. (Withdrawn) The method of claim 1 wherein said mucus secretion is gastrointestinal.
18. (Withdrawn) The method of claim 1 wherein said mucus secretion occurs in the nose, sinuses, throat, or lungs.
19. (Withdrawn) The method of claim 1 wherein said condition or disease is related to abdominal cramping.
20. (Withdrawn) The method of claim 1 wherein said condition or disease is irritable bowel syndrome.
21. (Withdrawn) The method of claim 1 wherein said condition or disease is a bleeding disorder.
22. (Withdrawn) The method of claim 1 wherein said condition or disease is a sleep disorder.
23. (Withdrawn) The method of claim 1 wherein said condition or disease is mastocytosis.
24. (Withdrawn) The method of claim 1 wherein said condition or disease is associated with elevated body temperature.

25. (Withdrawn) The method of claim 1 wherein said condition or disease is associated with ocular hypertension and glaucoma.
26. (Withdrawn) The method of claim 1 wherein said condition or disease is associated with ocular hypotension.
27. (Currently Amended) A pharmaceutical product comprising




or a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutically acceptable excipient;

wherein said product is packaged and labeled for the treatment or prevention of a disease or condition selected from the group consisting of allergic conditions, asthma, allergic asthma, allergic rhinitis, ~~atherosclerosis~~, blood coagulation disorders, bone disorders, cancer, cellular neoplastic transformations, chronic obstructive pulmonary diseases and other forms of lung inflammation, ~~congestive heart failure~~, ~~diabetic retinopathy~~, diseases or conditions requiring a treatment of anti-coagulation, diseases requiring control of bone formation and resorption, ~~fertility disorders~~, fever, ~~gangrene~~, ~~glaucoma~~, hypothermia, immune and autoimmune diseases, inflammatory conditions, ~~metastatic tumor growth~~, ~~migraine~~, mucus secretion disorders, nasal congestion, nasal inflammation, occlusive vascular diseases, ~~ocular hypertension~~, ~~ocular hypotension~~, osteoporosis, pain, perennial rhinitis, pulmonary congestion, pulmonary hypotension, ~~Raynaud's disease~~, rejection in ~~organ transplant and by-pass surgery~~, respiratory conditions, ~~rheumatoid arthritis~~, rhinorrhea, ~~shock~~, sleep disorders, and sleep-wake cycle disorders, ~~and tumor angiogenesis~~.

28. (Withdrawn) A method comprising


administering a prostaglandin D₂ antagonist to a mammal suffering from, or at risk of developing, a disease or condition selected from the group consisting of gastrointestinal tract disorders or diseases, hyperalgesia, allodynia, abdominal cramping, glaucoma, ocular hypertension, and ocular hypotension.

29. (Withdrawn) The method of claim 28 wherein said disease or condition is a gastrointestinal tract disorder or disease.
30. (Withdrawn) The method of claim 28 wherein said condition or disease is selected from the group consisting of peptic ulcer, heartburn, reflux esophagitis, erosive esophagitis, non-ulcer dyspepsia, infection by *Helicobacter pylori*, alrinitis, and irritable bowel syndrome.
31. (Withdrawn) The method of claim 28 wherein said condition or disease is irritable bowel syndrome.
32. (Withdrawn) The method of claim 28 wherein said condition or disease is hyperalgesia or allodynia.
33. (Withdrawn) The method of claim 28 wherein said condition or disease is abdominal cramping.
34. (Withdrawn) The method of claim 28 wherein said condition or disease is associated with ocular hypertension and glaucoma.
35. (Withdrawn) The method of claim 28 wherein said condition or disease is associated with ocular hypotension.
36. (Currently Amended) A compound ~~comprising of the formula~~



or a pharmaceutically acceptable salt or a prodrug thereof.

37. (Original) A pharmaceutical composition comprising




or a pharmaceutically acceptable salt or a prodrug thereof,
and a pharmaceutically acceptable excipient.

38. (Withdrawn) A method comprising

treating or preventing a condition or disease selected from the group consisting of allergic conditions, asthma, allergic asthma, allergic rhinitis, atherosclerosis, blood coagulation disorders, bone disorders, cancer, cellular neoplastic transformations, chronic obstructive pulmonary diseases and other forms of lung inflammation, congestive heart failure, diabetic retinopathy, diseases or conditions requiring a treatment of anti-coagulation, diseases requiring control of bone formation and resorption, fertility disorders, fever, gangrene, glaucoma, hypothermia, immune and autoimmune diseases, inflammatory conditions, metastatic tumor growth, migraine, mucus secretion disorders, nasal congestion, nasal inflammation, occlusive vascular diseases, ocular hypertension, ocular hypotension, osteoporosis, pain, perennial rhinitis, pulmonary congestion, pulmonary hypotension, Raynaud's disease, rejection in organ transplant and by-pass surgery, respiratory conditions, rheumatoid arthritis, rhinorrhea, shock, sleep disorders, sleep-wake cycle disorders, and tumor angiogenesis.

wherein



or a pharmaceutically acceptable salt or a prodrug thereof,
is administered to a mammal suffering from said condition or disease.